2 not yet recruiting, 1 active not recruiting, 1 completed. 3 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 2 | 3 | Not yet recruiting 2, Completed 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Everfront Biotech Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma Cerebraca wafer, Temozolomide (for relapsed malignant glioma) - Recurrent Glioblastoma, IDH-Wildtype | Phase 2 / Phase 3 | Not yet recruiting | Everfront Biotech Co., Ltd. | 175 | 2027-04-01 | 2026-09-10 |
| A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer EF-009 - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Everfront Biotech Co., Ltd. | 30 | 2027-04-01 | 2026-09-11 |
| To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers HK-001, Placebo control - Amyotrophic Lateral Sclerosis | Phase 1 | Active not recruiting | Everfront Biotech Co., Ltd. | 56 | 2021-02-01 | 2026-09-11 |
| A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma Cerebraca wafer - Recurrent GBM | Phase 1 / Phase 2 | Completed | Everfront Biotech Co., Ltd. | 22 | 2017-11-01 | 2024-09-19 |
Glioblastoma (2) · Amyotrophic Lateral Sclerosis (1) · Astrocytoma (1) · Glioma (1) · Pancreatic Neoplasms (1)
Temozolomide (1)
Taiwan (2) · United States (1)